Search

Your search keyword '"Soulie C"' showing total 150 results
Start Over Author "Soulie C"
150 results on '"Soulie C"'

2. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author

Soulie, C, Descamps, D, Grude, M, Schneider, V, Trabaud, M-A, Morand-Joubert, L, Delaugerre, C, Montes, B, Barin, F, Ferre, V, Raymond, S, Jeulin, H, Alloui, C, Yerly, S, Pallier, C, Reigadas, S, Signori-Schmuck, A, Guigon, A, Fafi-Kremer, S, Haim-Boukobza, S, Mirand, A, Maillard, A, Vallet, S, Roussel, C, Assoumou, L, Calvez, V, Flandre, P, Marcelin, A-G, Lagier, E, Le Guillou, H, Bettinger, D, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vabret, A, Henquell, C, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Schvoerer, E, Andre-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Brun-Vezinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Lambert-Niclot, S, Wirden, M, Chaix, ML, Amiel, C, Giraudeau, G, Brodard, V, Plantier, JC, Chaplain, C, Bourlet, T, Stoll-Keller, F, Schmitt, MP, Barth, H, Poggi, C, Izopet, J, Chaillon, A, Marque-Juillet, S, and Roque-Afonso, AM

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, HIV/AIDS, Infectious Diseases, Antimicrobial Resistance, Genetics, Clinical Research, Neurosciences, Infection, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genotype, HIV Infections, HIV-1, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Nervous System Diseases, Viral Load, ANRS Resistance AC11 Group, ARV, CSF, HIV, resistance, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.

Published
2015

3. Prevalence of baseline virological risk factors of increased virological failure to CAB+RPV among ARV-naive patients

Author

Charpentier, C., Storto, A., Soulie, C., Ferre, VM., Wirden, M., Joly, V., Lambert-Niclot, S., Morand-Joubert, L., Landman, R., Lacombe, K., Katlama, C., Ghosn, J., Marcelin, A-G., Calvez, V., and Descamps, D.

Subjects
Gene mutations -- Health aspects, Antiviral agents -- Patient outcomes, Drug resistance -- Genetic aspects, Genetic polymorphisms -- Health aspects, HIV infection -- Genetic aspects -- Development and progression -- Drug therapy, Health
Abstract

Background: Multivariable baseline factor analysis across CAB+RPV phase 3 studies recently showed that HIV-1 subtypes A6/A1, characterized by the L74I integrase (IN) polymorphism, and presence of RPV resistance-associated mutations (RAM), [...]

Published
2021
Full Text
View/download PDF

5. Outpatient Management of Patients With COVID-19

Author

Douillet, Delphine, primary, Penaloza, Andrea, additional, Mahieu, Rafaël, additional, Morin, François, additional, Chauvin, Anthony, additional, Gennai, Stéphane, additional, Schotte, Thibault, additional, Montassier, Emmanuel, additional, Thiebaud, Pierre-Clément, additional, Ghuysen François, Alexandre, additional, Dall’acqua, David, additional, Benhammouda, Kasarra, additional, Bissokele, Pascal, additional, Violeau, Mathieu, additional, Joly, Luc-Marie, additional, Andrianjafy, Hery, additional, Soulie, Caroline, additional, Savary, Dominique, additional, Riou, Jérémie, additional, Roy, Pierre-Marie, additional, Andrianjafy, H., additional, Baudin, L., additional, Benhammouda, K., additional, Bissolokele, P., additional, Brice, C., additional, Cayeux, C., additional, Casalino, E., additional, Casarin, C., additional, Chauvin, A., additional, Choquet, C., additional, Claessens, Y.-E., additional, Couturaud, Francis, additional, Dall’acqua, D., additional, Dobanton, B., additional, Douillet, D., additional, Dupriez, F., additional, Eyer, X., additional, Ferrand, L., additional, Gennai, S., additional, Ghuysen, A., additional, Greau-Chauchet, A., additional, Joly, L.-M., additional, Karam, H.-H., additional, Layot, M., additional, Leroy, A., additional, Lopez, R., additional, Mahieu, R., additional, Marchant, N., additional, Marjanovic, N., additional, Montassier, E., additional, Morin, F., additional, Penaloza, Baeza A., additional, Plantefeve, G., additional, Roy, P.-M., additional, Savary, D., additional, Schmidt, J., additional, Schotte, T., additional, Sebbane, M., additional, Soulie, C., additional, Soulat, L., additional, Steiner, C., additional, Thiebaud, P.-C., additional, Timsit, E., additional, Trabattoni, E., additional, and Violeau, M., additional

Published
2021
Full Text
View/download PDF

11. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

Author

Visseaux, Benoit, Assoumou, Lambert, Grude, Maxime, Carles, Marie-Josée, Meyer, Laurence, Roussel, Catherine, Le Guillou-Guillemette, H., Ducancelle, A., Courdavault, L, Alloui, C, Honore, P, Lepiller, Q., Bettinger, D., Bellecave, P., Pinson-Recordon, P, Tumiotto, Camille, Vallet, Sophie, Payan, C., Duthe, J, Leroux, M., Dina, Julia, Vabret, A., Mirand, A., Henquell, C., Bouvier-Alias, Magali, Simohamed, A, dos Santos, G, yerly, S, Gaille, C, Caveng, W, Chapalay, S, Calmy, A., Signori-Schmuck, Anne, Morand, Patrice, Pallier, Coralie, Raho-Moussa, M, Mole, M, Dulucq, M-J, Bocket, Laurence, Alidjinou, K, Ranger-Rogez, S, Trabaud, Mary-Anne, Icard, V, Tardy, J., Tamalet, C., Delamare, C, Montes, Brigitte, Schvoerer, E., Fenaux, H., Rodallec, A., André-Garnier, E., Ferre, Virginie, de Monte, Anne, Guigon, A., Guinard, J., Descamps, Diane, Charpentier, C., Peytavin, G., Tremaux, P, Avettand-Fenoel, V., Soulie, C., Malet, I., Wirden, Marc, Marcelin, A, Calvez, V., Flandre, P., Costagliola, D, Morand-Joubert, Laurence, Lambert-Niclot, S., Fofana, D, Boukli, N., Delaugerre, C., Chaix, Marie-Laure, Mahjoub, Nadia, Amiel, Corinne, Giraudeau, G, Beby-Defaux, A., Plainchamp, D, Maillard, Anne, Alessandri-Gradt, E, Leoz, M, Plantier, Jean-Christophe, Gantner, P, Delagreverie, H, Fafi-Kremer, Samira, Fischer, P, Raymond, Stéphanie, Izopet, Jacques, Chiabrando, J, Stefic, Karl, Barin, F., Fajole, G, Burgault, O, Marque-Juillet, S, Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), virology, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de recherche sur l'hétéroepitaxie et ses applications (CRHEA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Clermont-Ferrand, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Geneva University Hospital (HUG), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôtel-Dieu de Nantes, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Pharmacie de l'Hôpital Bichat, Centre de Recherches Pétrographiques et Géochimiques (CRPG), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Virologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Unité de Rétrovirologie, Hôpital Pontchaillou, Normandie Université (NU), Laboratoire de Virologie, CHU Strasbourg, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Service de bactériologie-virologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre national de référence du VIH INSERM U966, Université de Tours (UT), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Besançon, Université de Franche-Comté (UFC), Université Grenoble Alpes (UGA), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] (PEGASE), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Male, Etravirine, HIV Infections, Men who have sex with men, Sexual and Gender Minorities, chemistry.chemical_compound, Pre-exposure prophylaxis, 0302 clinical medicine, Pharmacology (medical), 030212 general & internal medicine, Phylogeny, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, education.field_of_study, Virulence, biology, [SDE.IE]Environmental Sciences/Environmental Engineering, Middle Aged, Viral Load, 3. Good health, Integrase, Infectious Diseases, Rilpivirine, Epidemiological Monitoring, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Female, France, Viral load, medicine.drug, Adult, Microbiology (medical), Genotype, Anti-HIV Agents, [SDE.MCG]Environmental Sciences/Global Changes, Population, Evolution, Molecular, 03 medical and health sciences, Drug Resistance, Viral, medicine, Humans, education, Pharmacology, 030306 microbiology, Genetic Variation, Sequence Analysis, DNA, [SDE.ES]Environmental Sciences/Environmental and Society, Virology, chemistry, Mutation, HIV-1, biology.protein, [SDE.BE]Environmental Sciences/Biodiversity and Ecology
Abstract

ObjectivesPatients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.MethodsA total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.ResultsPatients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P = 0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.ConclusionsSince 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.

Published
2019
Full Text
View/download PDF

12. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

Author

Katlama, C, Assoumou, L, Soulie, C, Beniguel, L, Fellahi, S, Peytavin, G, Marcelin, AG, Kolta, S, Capeau, J, Gibowski, S, Cardon, F, Costagliola, D, Bernard, L, Bottero, J, Bouchaud, O, Chidiac, C, Duvivier, C, Goujard, C, Gutierrez, MD, Martinez, E, Molina, JM, Morlat, P, Naqvi, A, Podzamczer, D, Poizot-Martin, I, Raffi, F, Reynes, J, Salmon-Ceron, D, Simon, A, Valantin, MA, Weiss, L, and Yazdanpanah, Y

Abstract

Background: Dual therapy combining integrase inhibitors and NNRTIs represents a promising regimen in ageing HIV-infected individuals with long exposure to nucleoside analogues and PIs. Methods: The ANRS 163 ETRAL trial (NCT02212379) was a 96 week, multicentre, single-arm study evaluating the efficacy and safety of raltegravir (400 mg twice daily)/etravirine (200 mg twice daily) in individuals >45 years, on a PI-containing regimen who were integrase inhibitor and etravirine naive. The primary endpoint was the proportion of participants with virological success, defined by the absence of virological failure up to week 48. Main secondary outcomes included evolution of metabolic parameters, CD4/CD8 count, bone mineral density and inflammatory markers. The study was designed to show an efficacy >90%, assuming a success rate >= 95%, with a power of 80% and a 5% type-1 error. Results: One hundred and sixty-five participants (median age 52 years, duration of ART 16.9 years, viral suppression 6.9 years and CD4 count 700 cells/mm3) were enrolled. By ITT analysis, viral suppression was maintained in 99.4% of participants (95% CI = 95.6%-99.9%) at week 48 and 98.7% (95% CI = 95.0%-99.7%) at week 96. Two virological failures occurred (week 24 and week 64) without emergence of integrase inhibitor resistance. Eight participants discontinued raltegravir/etravirine for adverse events, leading to a strategy success rate of 95.1% (95% CI = 90.5%-97.5%) at week 48 and 92.7% (95% CI = 87.5%-95.8%) at week 96. Over 96 weeks, lipid fractions improved (P < 0.001), CD4/CD8 ratio increased, IFN -induced protein 10 (IP-10) decreased (-8.1%), soluble CD14 decreased (-27%, P < 0.001) bone mineral density improved and BMI increased. Conclusions: Raltegravir plus etravirine dual therapy demonstrated durable efficacy in virologically suppressed ageing patients.

Published
2019

13. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries

Author

Ngo-Giang-Huong, Nicole, Huynh, T. H. K., Dagnra, A. Y., Toni, T. D., Maiga, A. I., Kania, D., Eymard-Duvernay, Sabrina, Peeters, Martine, Soulie, C., Peytavin, G., Rekacewicz, C., Chaix, M. L., Aghokeng Fobang, Avelin, Ayouba, Ahidjo (collab.), and ANRS Study Group

Subjects
parasitic diseases, virus diseases
Abstract

Background: ART in the developing world has moved to a new era with the WHO recommendation to test and immediately treat HIV-positive individuals. A high frequency of pretreatment HIV drug resistance (PDR) can compromise ART efficacy. Our study presents updated estimates of PDR in seven countries from West Africa (Burkina Faso, Cameroon, Cate d'Ivoire, Mali and Togo) and Southeast Asia (Thailand and Vietnam). Methods: Eligible study participants were adult ART initiators, recruited from December 2015 to November 2016 in major ART clinics in each country. HIV drug resistance (HIVDR) tests were performed for all specimens and interpretation was done using the Stanford algorithm. Results: Overall, 1153 participants were recruited and 1020 nt sequences were generated. PDR frequency among all initiators was 15.9% (95% CI: 13.8%-18.3%) overall, ranging from 9.6% and 10.2% in Burkina Faso and Thailand, respectively, 14.7% in Vietnam, 15.4% in Mali, 16.5% in Cote d'Ivoire and 19.3% in Cameroon, to 24.6% in Togo. The prevalence of NNRTI resistance mutations was 12%; NRTI and PI PDR prevalences were 4% and 3%, respectively. Conclusions: Our study shows that in most countries PDR exceeded 10%, warranting the conduct of nationally representative surveys to confirm this trend. In the meantime, actions to prevent drug resistance, including transition from NNRTIs to more robust drug classes should be urgently implemented.

Published
2019

14. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients

Author

Soulie, C. Santoro, M.M. Charpentier, C. Storto, A. Paraskevis, D. Di Carlo, D. Gennari, W. Sterrantino, G. Zazzi, M. Perno, C.F. Calvez, V. Descamps, D. Ceccherini-Silberstein, F. Marcelin, A.-G.

Subjects
virus diseases
Abstract

Background: Doravirine is a novel HIV-1 NNRTI recently shown to be non-inferior to both darunavir/ritonavir and efavirenz in combination therapy with two NRTIs in treatment-naive patients. Doravirine has an in vitro resistance profile that is distinct from other NNRTIs and retains activity against viruses containing the most frequently transmitted NNRTI mutations. Objectives: The aim of this study was to examine the prevalence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients in Europe. Methods: From 2010 to 2016, 9764 treatment-naive patients were tested for NNRTI antiretroviral drug resistance by bulk sequencing in Greece, Italy and France. We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C. Results: Among 9764 sequences, 53.0% and 47.0% of patients had B and non-B subtypes, respectively. Overall, the presence of at least one doravirine resistance-associated mutation (n " 137; 1.4%) or the K103N/Y181C mutations (n " 5; 0.05%) was very rare. The most prevalent mutations were V108I (n " 62; 0.6%), Y188L (n " 18; 0.2%), H221Y (n " 18; 0.2%) and Y318F (n " 23; 0.2%). The frequency of doravirine resistance-associated mutations was similar between B and non-B subtypes. In comparison, the prevalence of rilpivirine, etravirine, nevirapine and efavirenz resistance was higher whatever algorithm was used (ANRS: 8.5%, 8.1%, 8.3% and 3.9%, respectively; Stanford: 9.9%, 10.0%, 7.5% and 9.4%, respectively). Conclusions: The prevalence of doravirine resistance-associated mutations is very low in antiretroviral-naive patients. These results are very reassuring for doravirine use in naive patients. © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.

Published
2019

19. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients

Author

Bocket, L., primary, Peytavin, G., additional, Alidjinou, E. K., additional, Ajana, F., additional, Choisy, P., additional, Lê, M., additional, Charpentier, C., additional, Descamps, D., additional, Yazdanpanah, Yazdan, additional, Katlama, C., additional, Simon, A., additional, Calvez, V., additional, Marcelin, A.-G., additional, and Soulie, C., additional

Published
2016
Full Text
View/download PDF

21. Petrofabrics in fine-grained rims of Vigarano CV3 chondrite : insights from EBSD and AFM studies

Author

Soulie, C., benoit ildefonse, Libourel, G., Centre de Recherches Pétrographiques et Géochimiques (CRPG), Université de Lorraine (UL)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Géosciences Montpellier, Institut national des sciences de l'Univers (INSU - CNRS)-Université de Montpellier (UM)-Université des Antilles (UA)-Centre National de la Recherche Scientifique (CNRS), Manteau et Interfaces, Institut national des sciences de l'Univers (INSU - CNRS)-Université de Montpellier (UM)-Université des Antilles (UA)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Montpellier (UM)-Université des Antilles (UA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA)-Université de Montpellier (UM)-Institut national des sciences de l'Univers (INSU - CNRS), Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA)-Université de Montpellier (UM)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA)-Université de Montpellier (UM)-Institut national des sciences de l'Univers (INSU - CNRS), and Aigle, Gm

Subjects
[SDE.MCG] Environmental Sciences/Global Changes, Vigarano CV3 chondrite, [SDU.STU.GC]Sciences of the Universe [physics]/Earth Sciences/Geochemistry, EBSD, [SDE.MCG]Environmental Sciences/Global Changes, [SDU.STU.GC] Sciences of the Universe [physics]/Earth Sciences/Geochemistry
Abstract

Fine grained rims (FGR) are commonly encountered around chondrules and CAI’s in CV carbonaceouschondrites. They are mostly composed by very fine grained (mi- cron to submicron) iron rich olivine.Whether the iron rich olivines are of nebular or parent body origin stays a matter of debate ([1],[2], [3]).While chemical and petrographic characterizations are abundant in the literature, only few studies concerningmicrotextures and fabrics of these fine grained olivines are available [4], [5], [6]. Recent EBSD study in Allende has stirred up the debate, since a spherical fabricaround chondrules has been discovered, supporting a nebular origin [5]. In order to further investigate the relationship between chondrules and fine grained rims,we present here EBSD and AFM analyses in Vigarano CV3 chondrite.

Published
2013

22. Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.

Author

Peytavin, G., Seang, S., Schneider, L., Calin, R., Caby, F., Valantin, M. A., Tubiana, R., Katlama, C., Assoumou, L., Nguyen, T., Soulie, C., Marcelin, A. G., and Lê, M. P.

Subjects
DARUNAVIR, RITONAVIR, VIREMIA, HIV, DRUG resistance, DRUG resistance in microorganisms, HIV infections, VIRAL load, TREATMENT effectiveness, ANTI-HIV agents
Abstract

Background: Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation.Methods: Patients with HIV suppressed viraemia (plasma viral load <50 copies/mL for 12 months) under ART who had switched to darunavir/ritonavir monotherapy at 600/100 mg/day between 2013 and 2015 were included in this observational 48 week single-centre study. The primary outcome was the proportion of patients with virological success (defined as plasma viral load <50 copies/mL) at week 24. Secondary outcomes included treatment strategy success and resistance.Results: Thirty-one patients were included with the following baseline characteristics [median (IQR)]: age 52 years (47-57), CD4+ 649 cells/mm3 (463-813), ART duration 16.3 years (9.2-22.3), nadir CD4+ 195 cells/mm3 (144-261) and duration of HIV suppression 7.8 years (4.8-9.7). Prior to switch, ART consisted of PI monotherapy for 28 of 31 patients [darunavir/ritonavir 800/100 mg/day (n = 26), lopinavir/ritonavir (n = 1) and atazanavir/ritonavir (n = 1)] and a triple drug regimen for 3 of 31 patients. Within the 48 weeks of follow-up, no virological failure occurred and two patients discontinued 600/100 mg of darunavir/ritonavir due to side effects at week 16 and 40, leading to a virological suppression rate of 100% (95% CI = 89-100) at weeks 24 and 48. Strategy success rates were 96.8% (95% CI = 83.3-99.9) at week 24 and 93.5% (95% CI = 78.6-99.2) at week 48. Median (IQR) Ctrough values of 800/100 mg of darunavir/ritonavir and 600/100 mg of darunavir/ritonavir were 1537 ng/mL (1286-1724) and 1255 ng/mL (873-2161), respectively.Conclusions: A lower dose of darunavir/ritonavir used as monotherapy (600/100 mg/day) was highly effective in virologically suppressed HIV-infected patients. Further studies are needed to confirm these data. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

25. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali

Author

Fofana, D. B., primary, Soulie, C., additional, Balde, A., additional, Lambert-Niclot, S., additional, Sylla, M., additional, Ait-Arkoub, Z., additional, Diallo, F., additional, Sangare, B., additional, Cisse, M., additional, Maiga, I. A., additional, Fourati, S., additional, Koita, O., additional, Calvez, V., additional, Marcelin, A. G., additional, and Maiga, A. I., additional

Published
2014
Full Text
View/download PDF

26. Pitfalls of HIV genotypic tropism testing after treatment interruption

Author

Wirden, M., Soulie, C., Fourati, S., Valantin, M.A., Simon, A., Ktorza, N., Tubiana, R., Bonmarchand, M., Schneider, L., Calvez, V., Katlama, C., Marcelin, A.G., Wirden, M., Soulie, C., Fourati, S., Valantin, M.A., Simon, A., Ktorza, N., Tubiana, R., Bonmarchand, M., Schneider, L., Calvez, V., Katlama, C., and Marcelin, A.G.

Abstract

Item does not contain fulltext, OBJECTIVES: The genotypic method is reliable enough for the determination of tropism and largely preferred in Europe. However, careful interpretation is essential when assessing HIV genotypic resistance during treatment interruption (TI) due to the possible disappearance of resistant strains. The results of HIV genotypic tropism testing in such a context remain unknown. METHODS: First, we studied changes in tropism in patients included in a structured TI assay: the Reverse study. Second, we investigated the unexpected tropism switches from X4 to R5 recorded in our routine database. RESULTS: Tropism determination was possible in 21 patients of the Reverse study, 9 of whom had an X4 virus (43%) at baseline. Two patients displayed a change of tropism during TI, both switching from X4 to R5. Regarding the database investigation, 7 of the 222 patients with at least two plasma tropism determinations recorded in the database displayed a switch from X4 to R5. TI due to non-compliance at the time of the tropism change was reported for five of these seven patients. CONCLUSIONS: We have shown that the redistribution of the HIV population caused by TI could potentially result in X4 viruses becoming undetected and inappropriate prescription of a CCR5 receptor antagonist. Therefore, genotypic tropism results should be interpreted with caution in such a context.

Published
2013

27. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

Author

Lambert-Niclot, S., primary, Charpentier, C., additional, Storto, A., additional, Fofana, D., additional, Soulie, C., additional, Fourati, S., additional, Wirden, M., additional, Morand-Joubert, L., additional, Masquelier, B., additional, Flandre, P., additional, Calvez, V., additional, Descamps, D., additional, and Marcelin, A. G., additional

Published
2013
Full Text
View/download PDF

28. Lopinavir/Ritonavir Monotherapy as a Nucleoside Analogue–Sparing Strategy to Prevent HIV-1 Mother-to-Child Transmission: The ANRS 135 PRIMEVA Phase 2/3 Randomized Trial

Author

Tubiana, Roland, primary, Mandelbrot, Laurent, additional, Le Chenadec, Jérome, additional, Delmas, Sandrine, additional, Rouzioux, Christine, additional, Hirt, Deborah, additional, Treluyer, Jean-Marc, additional, Ekoukou, Dieudonné, additional, Bui, Eda, additional, Chaix, Marie-Laure, additional, Blanche, Stéphane, additional, Warszawski, Josiane, additional, Ngondi, J, additional, Chernai, N, additional, Teglas, JP, additional, Laurent, C, additional, Huyn, P, additional, Le Chenadec, J, additional, Delmas, S, additional, Warszawski, J, additional, Muret, P, additional, Baazia, Y, additional, Jeantils, V, additional, Lachassine, E, additional, Rodrigues, A, additional, Sackho, A, additional, Sagnet-Pham, I, additional, Tassi, S, additional, Breilh, D, additional, Iriard, X, additional, Andre, G, additional, Douard, D, additional, Reigadas, S, additional, Roux, D, additional, Louis, I, additional, Morlat, P, additional, Pedebosq, S, additional, Barre, J, additional, Estrangin, E, additional, Fauveau, E, additional, Garrait, V, additional, Ledudal, P, additional, Pichon, C, additional, Richier, L, additional, Thebault, A, additional, Touboul, C, additional, Bornarel, D, additional, Chambrin, V, additional, Clech, L, additional, Dubreuil, P, additional, Foix L'helias, L, additional, Picone, O, additional, Schoen, H, additional, Stralka, M, additional, Crenn-Hebert, C, additional, Floch-Tudal, C, additional, Hery, E, additional, Ichou, H, additional, Mandelbrot, L, additional, Meier, F, additional, Tournier, V, additional, Walter, S, additional, Chevojon, P, additional, Devidas, A, additional, Granier, M, additional, Khanfar-boudjemai, M, additional, Malbrunot, C, additional, Nguyen, R, additional, Ollivier, B, additional, Radideau, E, additional, Turpault, I, additional, Jault, T, additional, Barrail, A, additional, Colmant, C, additional, Fourcade, C, additional, Goujard, C, additional, Pallier, C, additional, Peretti, D, additional, Taburet, AM, additional, Bocket, L, additional, D'angelo, S, additional, Godart, F, additional, Hammou, Y, additional, Houdret, N, additional, Mazingue, F, additional, Thielemans, B, additional, Brochier, C, additional, Cotte, L, additional, Januel, F, additional, Le Thi, T, additional, Gagneux, MC, additional, Bozio, A, additional, Massardier, J, additional, Kebaïli, K, additional, Ben, Akli K, additional, Heller-Roussin, B, additional, Riehl, C, additional, Roos, S, additional, Taccot, F, additional, Winter, C, additional, Arias, J, additional, Brunet-François, C, additional, Dailly, E, additional, Flet, L, additional, Gournay, V, additional, Mechinaud, F, additional, Reliquet, V, additional, Winner, N, additional, Peytavin, G, additional, Bardin, C, additional, Boudjoudi, N, additional, Compagnucci, A, additional, Guerin, C, additional, Krivine, A, additional, Pannier, E, additional, Salmon, D, additional, Treluyer, JM, additional, Firtion, G, additional, Ayral, D, additional, Ciraru-Vigneron, N, additional, Mazeron, MC, additional, Rizzo Badoin, N, additional, Trout, H, additional, Benachi, A, additional, Boissand, C, additional, Bonnet, D, additional, Boucly, S, additional, Blanche, S, additional, Chaix, ML, additional, Duvivier, C, additional, Parat, S, additional, Cayol, V, additional, Oucherif, S, additional, Rouzioux, C, additional, Viard, JP, additional, Bonmarchand, M, additional, De Montgolfier, I, additional, Dommergues, M, additional, Fievet, MH, additional, Iguertsira, M, additional, Pauchard, M, additional, Quetin, F, additional, Soulie, C, additional, Tubiana, R, additional, Faye, A, additional, Magnier, S, additional, Bui, E, additional, Carbonne, B, additional, Daguenel Nguyen, A, additional, Harchi, N, additional, Meyohas, MC, additional, Poirier, JM, additional, Rodriguez, J, additional, Hervé, F, additional, Pialloux, G, additional, Dehee, A, additional, Dollfus, C, additional, Tillous Borde, I, additional, Vaudre, G, additional, Wallet, A, additional, Allemon, MC, additional, Bolot, P, additional, Boussairi, A, additional, Chaplain, C, additional, Ekoukou, D, additional, Ghibaudo, N, additional, Kana, JM, additional, Khuong, MA, additional, Weil, M, additional, Entz-Werle, N, additional, Livolsi Lutz, P, additional, Beretz, L, additional, Cheneau, M, additional, Partisani, ML, additional, Schmitt, MP, additional, Acar, P, additional, Armand, E, additional, Berrebi, A, additional, Guibaud Plo, C, additional, Lavit, M, additional, Nicot, F, additional, Tricoire, J, additional, Ajana, F, additional, and Huleux, T, additional

Published
2013
Full Text
View/download PDF

31. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

Author

Lambert-Niclot, S., primary, Charpentier, C., additional, Storto, A., additional, Fofana, D. B., additional, Soulie, C., additional, Fourati, S., additional, Visseaux, B., additional, Wirden, M., additional, Morand-Joubert, L., additional, Masquelier, B., additional, Flandre, P., additional, Calvez, V., additional, Descamps, D., additional, and Marcelin, A.- G., additional

Published
2013
Full Text
View/download PDF

33. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

Author

Fourati, S., primary, Lambert-Niclot, S., additional, Soulie, C., additional, Malet, I., additional, Valantin, M. A., additional, Descours, B., additional, Ait-Arkoub, Z., additional, Mory, B., additional, Carcelain, G., additional, Katlama, C., additional, Calvez, V., additional, and Marcelin, A. G., additional

Published
2012
Full Text
View/download PDF

38. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Author

Soulie, C., primary, Fourati, S., additional, Lambert-Niclot, S., additional, Malet, I., additional, Wirden, M., additional, Tubiana, R., additional, Valantin, M.-A., additional, Katlama, C., additional, Calvez, V., additional, and Marcelin, A.-G., additional

Published
2010
Full Text
View/download PDF

43. HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

Author

Recordon-Pinson, P., Raymond, S., Bellecave, P., Marcelin, A. G., Soulie, C., Descamps, D., Calvez, V., Harrigan, P. R., Fleury, H., Izopet, J., and Masquelier, B.

Abstract

ABSTRACTThere is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novoselection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.

Published
2012
Full Text
View/download PDF

50. Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.

Author

Marcelin AG, Soulie C, Wirden M, Barriere G, Durand F, Charpentier C, Descamps D, and Calvez V

Abstract

Background: Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these regimens., Objectives: The Virostar-1 study objective is to analyse the emergence of resistance-associated mutations (RAMs) over 3 years with DTG-based 2DRs and DTG- or bictegravir (BIC)-based 3DRs in people living with HIV (PLWH) experiencing a VF (FL or SL)., Methods: Retrospective analysis of genotypic resistance detected at the time of a FL or SL VF with BIC/FTC/TAF, DTG/ABC/3TC, DTG/3TC and DTG/RPV between 2019 and 2022 was conducted from a French multicentre database. VF was defined as two consecutive HIV-1 plasma viral loads > 50 c/mL. Sanger assays were performed at VF within standard clinical care. Resistance mutations were reported using the ANRS algorithm. Selection biases prevent group comparisons., Results: During the period, N = 5986 PLWH were followed either in FL or SL. The VF rate was overall low: BIC/FTC/TAF, 6.8%; DTG/ABC/3TC, 7.5%; DTG/3TC, 5.1%; and DTG/RPV, 2.1%. Some emergent InSTI or NRTI RAMs were detected with BIC/FTC/TAF 4%, DTG/ABC/3TC 8.5%, DTG/3TC 18% and 39% emergent NNRTI RAMs with DTG/RPV. However, a complete absence of dual resistance against NRTIs and InSTIs was observed., Conclusions: We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results